Company Update: Johnson & Johnson (NYSE:JNJ) – 9:01 am Johnson & Johnson: Two-year data from INNOVATION trial on INCRAFT AAA stent graft system continues to demonstrate safety and performance in treatment of abdominal aortic Aneurysms

[Briefing.com] – 9:01 am Johnson & Johnson: Two-year data from INNOVATION trial on INCRAFT AAA stent graft system continues to demonstrate safety and performance in treatment of abdominal aortic . . . → Read More: Company Update: Johnson & Johnson (NYSE:JNJ) – 9:01 am Johnson & Johnson: Two-year data from INNOVATION trial on INCRAFT AAA stent graft system continues to demonstrate safety and performance in treatment of abdominal aortic Aneurysms Similar Articles: Amgen Inc. (NASDAQ:AMGN) – Amgen cholesterol drug succeeds in late-stage trial AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial Stock market seasonality mid-year update